About: Burden of Human Metapneumovirus Infections in Cancer Patients: Risk Factors and Outcomes

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Burden of Human Metapneumovirus Infections in Cancer Patients: Risk Factors and Outcomes Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Burden of Human Metapneumovirus Infections in Cancer Patients: Risk Factors and Outcomes
Creator	Ariza-Heredia, Ella Kmeid, Joumana Chemaly, Roy Fidsa, Chaer, Firas Chitra, ; Dimpy, ; Hosing, M Mulanovich, E Shah, P Victor, ;
Source	Medline; PMC
abstract	BACKGROUND: Human metapneumovirus (hMPV) causes upper and lower respiratory tract infections (URI and LRI, respectively) in healthy and immunocompromised patients; however, its clinical burden in patients with cancer remains unknown. METHODS: In a retrospective study of all laboratory-confirmed hMPV infections treated at our institution between April 2012 and May 2015, we determined clinical characteristics, risk factors for progression to LRI, treatment, and outcomes in patients with cancer. RESULTS: We identified 181 hMPV infections in 90 (50%) patients with hematologic malignancies (HM), 57 (31%) hematopoietic cell transplantation (HCT) recipients, and 34 patients (19%) with solid tumors. Most patients (92%) had a community-acquired infection, presented with URI (67%), and 43% developed LRI (59 presented with LRI and 19 progressed from URI to LRI). On multivariable analysis, an underlying HM (adjusted odds ratio [aOR], 3.11(1.12-8.64); P=0.029), nosocomial infection (aOR, 26.9 (2.79-259.75); P=0.004), and hypoxia (SpO2 ≤ 92%) at presentation (aOR, 9.61(1.98-46.57); P = 0.005) were independent factors associated with LRI. All-cause mortality at 30 days from hMPV diagnosis was low (4%) and patients with LRI had a 10% mortality rate at day 30 from diagnosis; whereas, patients with URI had 0% mortality rate. CONCLUSIONS: hMPV infections in patients with cancer may cause significant morbidity, especially for those with underlying HM who may develop an LRI. Despite high morbidity and the lack of directed antiviral therapy for hMPV infections, mortality at day 30 from this infection remained low in this studied population.
has issue date	2017-02-08(xsd:dateTime)
bibo:doi	10.1002/cncr.30599
bibo:pmid	28178369
has license	bronze-oa
sha1sum (hex)	0d72a0abdbcb41af16e34e296132082188a828f6
schema:url	https://doi.org/10.1002/cncr.30599
resource representing a document's title	Burden of Human Metapneumovirus Infections in Cancer Patients: Risk Factors and Outcomes
has PubMed Central identifier	PMC5459658
has PubMed identifier	28178369
schema:publication	Cancer
resource representing a document's body	covid:0d72a0abdbcb41af16e34e296132082188a828f6#body_text
is schema:about of	named entity 'MORTALITY' named entity 'ALL-CAUSE MORTALITY' named entity 'POPULATION' named entity 'HEMATOLOGIC MALIGNANCIES' named entity 'RESULTS' named entity 'CONFIDENCE INTERVAL' named entity 'DAYS' named entity 'DIAGNOSIS' named entity 'SIGNIFICANT' named entity 'MORTALITY RATE' named entity 'DAY' named entity 'ITS' named entity 'HUMAN METAPNEUMOVIRUS' named entity 'DIRECTED' named entity 'UNKNOWN' named entity 'TREATMENT' named entity 'CONCLUSIONS' named entity 'PRESENTATION' named entity 'SOLID TUMORS' named entity 'INDEPENDENT' named entity 'multivariable analysis' named entity 'morbidity' named entity 'risk factors' named entity 'URI' named entity 'URIs' named entity 'retrospective study' named entity 'hypoxia' named entity 'Human Metapneumovirus' named entity '95% CI' named entity 'respiratory viral infections' named entity 'graft-versus-host' named entity 'immunosuppression' named entity 'RSV' named entity 'relapse' named entity 'endotracheal tube' named entity 'virulence' named entity 'hMPV' named entity 'antiviral therapy' named entity 'ALC' named entity 'subgroup analysis' named entity 'cytomegalovirus' named entity 'risk factors' named entity 'oxygen saturation' named entity 'refractory' named entity 'retrospective study' named entity 'Oxygen saturation' named entity 'young children' named entity 'ribavirin' named entity 'hMPV' named entity 'odds ratios' named entity 'virus' named entity 'URI' named entity 'autologous' named entity 'ANC' named entity 'nosocomial infections' named entity 'hMPV' named entity 'hMPV' named entity 'autologous' named entity 'viruses' named entity 'case reports' named entity 'sample size' named entity 'FEV1' named entity 'URIs' named entity 'clinical characteristics' named entity 'hMPV' named entity 'immunocompromised' named entity 'Leukemia' named entity 'higher risk' named entity 'allogeneic' named entity 'symptom' named entity 'intravenous immunoglobulins'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software